💊

MANKIND

: A Prescription for Profits!

📈 Q4 FY25 Results – Beating Expectations: 🧾 Net Profit: ₹421 crore (vs. ₹367 crore expected) – beats the street 💸 Revenue: ₹3,079 crore – up 27% YoY, led by domestic demand 🧬 What’s Driving the Surge? 💉 Strong growth in chronic therapy (diabetes, hypertension, etc.) 📈 Market share in chronic segment rose from 37.5% → 39.2% 🏥 Rural and tier-2/3 cities showing stronger sales momentum 🤝 Strategic Move: Acquired Bharat Serums & Vaccines for $1.6 billion – expands biotech & women’s health portfolio 🔮 Investor Insight: Focused on branded generics in India (93% of revenue) Low dependence on US market = more domestic resilience R&D-backed pipeline + aggressive marketing = long-term growth story Watch out for

. What are your thoughts?